Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AREVA
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights AI trends in medtech, Exec Chats with iRhythm and medical robotics authority Moshe Shoham, and key FDA updates.
Minute Insight: Viz.ai Raises $100M To Expand AI-Based Platform To Detect Diseases, Coordinate Care In Hospitals
The latest funding round, led by Tiger Global Management and Insight Partners, values the company at $1.2bn.
Strategics pursuing high growth M&A plays are often ready to pay a premium price for a target. But with medtech valuations at historic highs, they cannot afford to do that every time. One solution is to take a strategic stake and build early, according to an AdvaMed panel hosted by EY’s John Babitt.
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.
- Generic Drugs
- Other Names / Subsidiaries
- AREVA Resources Canada